Treatment of cancer-related anemia with epoetin alfa: a review

Erminia Ferrario(Fondazione IRCCS Istituto Nazionale dei Tumori), Emilio Bajetta(Fondazione Lanza), Sara De Dosso(Institute of Oncology Research), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo Bidoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Leonardo Ferrari(Fondazione IRCCS Istituto Nazionale dei Tumori), Daniela De Candis(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberto Buzzoni(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cancer Treatment Reviews
May 29, 2004
10.1016/j.ctrv.2004.04.005
Cited by 60

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780